News
CEGYR leads as first fertility clinic globally to use Future Fertility’s AI-powered egg assessment on all cycles
Latin America has captured international attention due to its popularity as a destination for medical tourism and a surging demand for fertility services
Following their milestone 40th anniversary celebration, CEGYR, one of Latin America’s oldest and largest fertility clinics, has announced a groundbreaking move to use Future Fertility’s AI-powered oocyte assessments on every treatment cycle.
With this large-scale adoption, they will be the first clinic globally to provide personalised oocyte quality insights to every egg freezing and IVF-ICSI patient, through VIOLET™ and MAGENTA™ reports, which have been tailored to each patient type, respectively.
In addition, oocyte assessments will be performed on all donor eggs to ensure quality control and balance within batches.
CEGYR’s announcement comes during a period of strong growth within the Latin American fertility market, which has captured international attention due to its increasing popularity as a destination for medical tourism and a surging demand for fertility services that continues to be underserved in this region.
Under the guidance of Dr Sergio Papier, a globally respected expert in reproductive medicine, CEGYR has earned a reputation for its leadership in scientific research within the field.
Additionally, the clinic has recently launched a precision medicine unit, which offers patients more personalised treatments leveraging advanced technologies like Future Fertility’s AI solutions.
This approach aims to enhance individual outcomes, marking another significant step in their commitment to elevating fertility care standards.
Dr Papier did highlight, however, that the current standard for oocyte quality assessment is ripe for change.
“CEGYR recognises how pivotal oocytes are to fertility success, and there has been a need for an improved standard of care in assessing oocyte quality beyond the use of population health statistics.
“Future Fertility’s tools were a natural choice for us in driving this change for our patients, as they are internationally recognised leaders in this area.
“They’ve put in the work to validate their model’s performance across many markets globally and have also validated across both time-lapse and microscope-based image capture to serve different lab set-ups.”
CEGYR’s decision to integrate Future Fertility’s AI-powered oocyte quality assessment tools into all their cycles not only marks a significant milestone for the clinic but also underscores the ongoing transformation of Latin America’s fertility landscape.
With advanced technologies and precision medicine, the region is poised to provide world-class fertility care, attracting patients seeking effective and innovative solutions for their reproductive health from around the globe.
“We’re excited to partner with an esteemed and globally renowned institution like CEGYR as we pave the way to a new standard of care in oocyte assessment for Latin America,” said Christy Prada, Future Fertility’s CEO.
“As this is the first time a partner has adopted our technology across all cycles, we’re keen to work with CEGYR to understand how this scaled technology adoption can drive clinic-wide benefits, from lab efficiencies to improved patient experience.”
Other clinics within the Eugin Group, the international parent network of CEGYR, have also integrated Future Fertility’s technology.
In Toronto, TRIO Fertility, a longstanding partner of Future Fertility, has recently introduced the commercial use of MAGENTA™ oocyte quality reports for their IVF patients.
The team at TRIO were also early adopters of VIOLET™ assessments for their egg freezing patients at their original facility and have since incorporated these personalised oocyte outcome predictions into all cycles at their newly established clinic, EVOLVE, dedicated exclusively to egg freezing.
The Femtech World Awards are set to recognise the people, organisations and innovations revolutionising how we treat and diagnose cancer in women.
Now in its third year, the Femtech World Awards celebrates the very best of female-led and focused health innovation, spanning menopause, fertility, cardiovascular disease and beyond.
The Women’s Cancer Innovation award will honour a groundbreaking innovation dedicated to the prevention, early detection treatment or ongoing care of cancers that uniquely or disproportionately affect women.
The winner will have demonstrated exceptional progress in advancing research, technology or patient-centred solutions that improve outcomes and quality of life.
This award celebrates those driving transformative change in the fight against women’s cancers.
The Women’s Cancer Innovation Award is sponsored by Endomag.
Endomag believes everyone deserves a better standard of cancer care – that’s why they design their cancer localisation technologies with both the clinician and patient in mind.
Many leading hospitals across the world use their unique solutions to help breast cancer patients avoid surgery when it isn’t needed, and experience better outcomes when it is.
Their Magseed marker is a tiny, non-radioactive seed, ideal for accurately marking tumours and lymph nodes, while the Magtrace lymphatic tracer is the world’s first, long-lasting, non-radioactive dual tracer for lymphatic mapping.
Paired with the Sentimag localisation platform, they have now been widely proven across over 200 clinical studies, featuring more than 20,000 patients.
This award is one of 10 featuring at the event, which last year attracted entries from across the UK, Europe and North America.
Award winners will receive a trophy and the opportunity to be interviewed by Femtech World.
Both winners and shortlisted entries will receive extensive coverage across all Femtech World platforms.
Find out more and enter for free here.
Two designer perfumes have been recalled over a banned chemical linked to fertility risk and harm to unborn children.
Hello by Lionel Richie and Hot by United Colours of Benetton, both sold by discount chain Savers Health and Beauty, have been recalled in a notice from the Office for Product Safety and Standards.
The products contain butylphenyl methylpropional (BMHCA), also known as lilial, a synthetic floral fragrance classified as toxic to reproductive health.
The chemical, which mimics a lily of the valley scent, was used in many cosmetics and household products until March 2022, when it was banned in the UK and EU.
According to the notice, BMHCA can harm the reproductive system and the health of unborn children, and may cause skin sensitisation.
The Office for Product Safety and Standards said: “Affected products have been recalled by Savers Health and Beauty. Customers should return any of the above products purchased at a Savers store to the place of purchase, where they will be issued a full refund.
“Only products purchased in Savers Health and Beauty stores with the barcodes listed are affected by this recall. If you are unsure if you have one of the above products, please contact Savers Health and Beauty on help@savers.co.uk.”
The initial warning about the items was issued last month, with products recalled from customers on Wednesday.
Savers said in a statement that it would like to apologise for any inconvenience caused.
Affected products include Hello by Lionel Richie Femme and Homme in 30ml, 50ml and 100ml sizes, and Benetton Hot 100ml EDT.
Pregnant women exposed to ‘forever chemicals’ could be at greater risk of developing gestational diabetes, a recent study suggests.
PFAS (per- and polyfluoroalkyl substances) are toxic chemicals that do not break down in the body, leaching from non-stick cookware, waterproof textiles and takeaway containers into food or via skin contact and building up in vital organs.
Researchers analysed 79 animal and human studies evaluating the relationship between PFAS, diabetes and pregnancy.
They found that higher exposure led to consistently higher insulin resistance, where the body’s cells do not respond properly to insulin, and higher rates of gestational diabetes.
The research was conducted at the Icahn School of Medicine at Mount Sinai in New York City.
Dr Sandra India-Aldana, co-first study author, said: “This is the most comprehensive synthesis of evidence to date examining how PFAS exposure relates not only to diabetes risk, but also to the underlying clinical markers that precede disease.
“Our findings suggest that pregnancy may be a particularly sensitive window during which PFAS exposure may increase risk for gestational diabetes.
Gestational diabetes has been rising for the past decade.
In babies, it may lead to high birth weight, preterm labour and increased risk of obesity and type 2 diabetes later in life.
Mothers may also face higher risk of high blood pressure and developing diabetes in future.
Dr Xin Yu, co-first study author, said: “Gestational diabetes has lasting implications for both mother and child.
“This research supports the growing recognition that environmental exposures like PFAS should be part of conversations around preventive care and risk reduction during pregnancy.”
Dr Damaskini Valvi, senior study author, said: “These results are alarming as almost everyone is exposed to PFAS, and gestational diabetes can have severe long-term complications for mothers and their children.
“We need larger longitudinal studies with well-characterised type 1 and type 2 diabetes cases to fully characterise PFAS impacts on diabetes risk and its long-term complications for affected individuals and their families.
“These results underscore the importance of considering PFAS and other hazardous environmental chemical exposures as part of comprehensive clinical risk assessment and preventive care, particularly during pregnancy.”
-
Wellness1 day agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks ago2025: The year IVF innovation went from lab to life
-
Insight1 week ago‘Rejuvenated’ eggs raise hopes for improved IVF outcomes
-
News4 weeks agoCan biotech help close the fertility gap? Inside the race to improve egg quality
-
Insight4 weeks agoAI-driven digital tool delivers sustained blood pressure reductions, study finds
-
Insight3 days agoHigher maternal blood pressure increases risk of pregnancy complications, study finds
-
Features3 days agoWomen’s health enters a new era – the trends shaping femtech in 2026
-
Features3 days agoBest menopause apps and products for 2026